Lonza and Stipple Bio have entered a multi-target licensing agreement to advance next-generation antibody-drug conjugate therapies for precision oncology. This collaboration leverages specialized platforms to identify tumor-specific cell surface epitopes while utilizing advanced bioconjugation and polar spacer technologies to improve therapeutic efficacy. By combining discovery capabilities with scalable manufacturing, the partnership aims to develop better-tolerated cancer treatments that significantly minimize toxic side effects for patients.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
3
Ali NematiWritten by Ali
